Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?

Edward Norris-Cervetto, Terry D. Butters, Catherine Martin, S. Modok, Raymond A. Dwek, Richard Callaghan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Recently developed glucosylceramide synthase inhibitors with enhanced hydrophobicity display increased bioavailability in the central nervous system (CNS). Have these improvements come at a potential risk given that the improved glucosylceramide synthase inhibitors bear the hallmarks of P-glycoprotein substrates? This question warrants attention given the potential to induce adverse drug interactions or toxicity, if glucosylceramide synthase inhibitors are administered with other P-glycoprotein substrates. The aim of this study was to determine if glucosylceramide synthase inhibitors are substrates for the multidrug transporter P-glycoprotein. Direct measurements of glucosylceramide synthase inhibitors binding to P-glycoprotein were examined, as was their ability to modulate transport by the protein. The more hydrophobic glucosylceramide synthase inhibitors caused a reduction in drug binding to P-glycoprotein. However, the compounds did not achieve this by direct interaction with the protein, but through a general membrane perturbation. Furthermore, the alterations in drug-P-glycoprotein interaction did not manifest as altered cellular accumulation of glucosylceramide synthase inhibitors or altered efficacy to reduce cellular glycolipid levels. Consequently, P-glycoprotein expression will not contribute significantly to the pharmacokinetic profile of the iminosugar glucosylceramide synthase inhibitors.

Original languageEnglish
Pages (from-to)195-204
Number of pages10
JournalEuropean Journal of Pharmacology
Volume530
Issue number3
DOIs
Publication statusPublished - Jan 20 2006

Fingerprint

ceramide glucosyltransferase
P-Glycoprotein
Biological Availability
Glycolipids
Drug-Related Side Effects and Adverse Reactions
Hydrophobic and Hydrophilic Interactions
Drug Interactions
Pharmaceutical Preparations

Keywords

  • Bioavailability
  • Deoxygalactonojirimycin
  • Drug transport
  • Glucosylceramide synthase inhibitor
  • Glycolipid
  • P-glycoprotein

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors? / Norris-Cervetto, Edward; Butters, Terry D.; Martin, Catherine; Modok, S.; Dwek, Raymond A.; Callaghan, Richard.

In: European Journal of Pharmacology, Vol. 530, No. 3, 20.01.2006, p. 195-204.

Research output: Contribution to journalArticle

Norris-Cervetto, Edward ; Butters, Terry D. ; Martin, Catherine ; Modok, S. ; Dwek, Raymond A. ; Callaghan, Richard. / Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?. In: European Journal of Pharmacology. 2006 ; Vol. 530, No. 3. pp. 195-204.
@article{e4b4966000664fcd94435e05fcc4d4eb,
title = "Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?",
abstract = "Recently developed glucosylceramide synthase inhibitors with enhanced hydrophobicity display increased bioavailability in the central nervous system (CNS). Have these improvements come at a potential risk given that the improved glucosylceramide synthase inhibitors bear the hallmarks of P-glycoprotein substrates? This question warrants attention given the potential to induce adverse drug interactions or toxicity, if glucosylceramide synthase inhibitors are administered with other P-glycoprotein substrates. The aim of this study was to determine if glucosylceramide synthase inhibitors are substrates for the multidrug transporter P-glycoprotein. Direct measurements of glucosylceramide synthase inhibitors binding to P-glycoprotein were examined, as was their ability to modulate transport by the protein. The more hydrophobic glucosylceramide synthase inhibitors caused a reduction in drug binding to P-glycoprotein. However, the compounds did not achieve this by direct interaction with the protein, but through a general membrane perturbation. Furthermore, the alterations in drug-P-glycoprotein interaction did not manifest as altered cellular accumulation of glucosylceramide synthase inhibitors or altered efficacy to reduce cellular glycolipid levels. Consequently, P-glycoprotein expression will not contribute significantly to the pharmacokinetic profile of the iminosugar glucosylceramide synthase inhibitors.",
keywords = "Bioavailability, Deoxygalactonojirimycin, Drug transport, Glucosylceramide synthase inhibitor, Glycolipid, P-glycoprotein",
author = "Edward Norris-Cervetto and Butters, {Terry D.} and Catherine Martin and S. Modok and Dwek, {Raymond A.} and Richard Callaghan",
year = "2006",
month = "1",
day = "20",
doi = "10.1016/j.ejphar.2005.11.038",
language = "English",
volume = "530",
pages = "195--204",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?

AU - Norris-Cervetto, Edward

AU - Butters, Terry D.

AU - Martin, Catherine

AU - Modok, S.

AU - Dwek, Raymond A.

AU - Callaghan, Richard

PY - 2006/1/20

Y1 - 2006/1/20

N2 - Recently developed glucosylceramide synthase inhibitors with enhanced hydrophobicity display increased bioavailability in the central nervous system (CNS). Have these improvements come at a potential risk given that the improved glucosylceramide synthase inhibitors bear the hallmarks of P-glycoprotein substrates? This question warrants attention given the potential to induce adverse drug interactions or toxicity, if glucosylceramide synthase inhibitors are administered with other P-glycoprotein substrates. The aim of this study was to determine if glucosylceramide synthase inhibitors are substrates for the multidrug transporter P-glycoprotein. Direct measurements of glucosylceramide synthase inhibitors binding to P-glycoprotein were examined, as was their ability to modulate transport by the protein. The more hydrophobic glucosylceramide synthase inhibitors caused a reduction in drug binding to P-glycoprotein. However, the compounds did not achieve this by direct interaction with the protein, but through a general membrane perturbation. Furthermore, the alterations in drug-P-glycoprotein interaction did not manifest as altered cellular accumulation of glucosylceramide synthase inhibitors or altered efficacy to reduce cellular glycolipid levels. Consequently, P-glycoprotein expression will not contribute significantly to the pharmacokinetic profile of the iminosugar glucosylceramide synthase inhibitors.

AB - Recently developed glucosylceramide synthase inhibitors with enhanced hydrophobicity display increased bioavailability in the central nervous system (CNS). Have these improvements come at a potential risk given that the improved glucosylceramide synthase inhibitors bear the hallmarks of P-glycoprotein substrates? This question warrants attention given the potential to induce adverse drug interactions or toxicity, if glucosylceramide synthase inhibitors are administered with other P-glycoprotein substrates. The aim of this study was to determine if glucosylceramide synthase inhibitors are substrates for the multidrug transporter P-glycoprotein. Direct measurements of glucosylceramide synthase inhibitors binding to P-glycoprotein were examined, as was their ability to modulate transport by the protein. The more hydrophobic glucosylceramide synthase inhibitors caused a reduction in drug binding to P-glycoprotein. However, the compounds did not achieve this by direct interaction with the protein, but through a general membrane perturbation. Furthermore, the alterations in drug-P-glycoprotein interaction did not manifest as altered cellular accumulation of glucosylceramide synthase inhibitors or altered efficacy to reduce cellular glycolipid levels. Consequently, P-glycoprotein expression will not contribute significantly to the pharmacokinetic profile of the iminosugar glucosylceramide synthase inhibitors.

KW - Bioavailability

KW - Deoxygalactonojirimycin

KW - Drug transport

KW - Glucosylceramide synthase inhibitor

KW - Glycolipid

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=30444460584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444460584&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2005.11.038

DO - 10.1016/j.ejphar.2005.11.038

M3 - Article

C2 - 16403499

AN - SCOPUS:30444460584

VL - 530

SP - 195

EP - 204

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -